These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19012503)

  • 1. SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies.
    Pinter-Brown LC
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1883-7. PubMed ID: 19012503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.
    Bartlett NL; Younes A; Carabasi MH; Forero A; Rosenblatt JD; Leonard JP; Bernstein SH; Bociek RG; Lorenz JM; Hart BW; Barton J
    Blood; 2008 Feb; 111(4):1848-54. PubMed ID: 18079362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
    Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD30: an important new target in hematologic malignancies.
    Deutsch YE; Tadmor T; Podack ER; Rosenblatt JD
    Leuk Lymphoma; 2011 Sep; 52(9):1641-54. PubMed ID: 21619423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity.
    Shen Y; Yang T; Cao X; Zhang Y; Zhao L; Li H; Zhao T; Xu J; Zhang H; Guo Q; Cai J; Gao B; Yu H; Yin S; Song R; Wu J; Guan L; Wu G; Jin L; Su Y; Liu Y
    MAbs; 2019; 11(6):1149-1161. PubMed ID: 31161871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
    Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
    Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.
    Cerveny CG; Law CL; McCormick RS; Lenox JS; Hamblett KJ; Westendorf LE; Yamane AK; Petroziello JM; Francisco JA; Wahl AF
    Leukemia; 2005 Sep; 19(9):1648-55. PubMed ID: 16049514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.
    Oflazoglu E; Stone IJ; Gordon KA; Grewal IS; van Rooijen N; Law CL; Gerber HP
    Blood; 2007 Dec; 110(13):4370-2. PubMed ID: 17909075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
    Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
    BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
    Ansell SM; Horwitz SM; Engert A; Khan KD; Lin T; Strair R; Keler T; Graziano R; Blanset D; Yellin M; Fischkoff S; Assad A; Borchmann P
    J Clin Oncol; 2007 Jul; 25(19):2764-9. PubMed ID: 17515574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
    N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo.
    Maeda N; Muta H; Oflazoglu E; Yoshikai Y
    Cancer Sci; 2010 Jan; 101(1):224-30. PubMed ID: 19799612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD30 as a therapeutic target for lymphoma.
    Schirrmann T; Steinwand M; Wezler X; Ten Haaf A; Tur MK; Barth S
    BioDrugs; 2014 Apr; 28(2):181-209. PubMed ID: 24043362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders.
    Duvic M; Reddy SA; Pinter-Brown L; Korman NJ; Zic J; Kennedy DA; Lorenz J; Sievers EL; Kim YH
    Clin Cancer Res; 2009 Oct; 15(19):6217-24. PubMed ID: 19789316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.
    Borchmann P; Treml JF; Hansen H; Gottstein C; Schnell R; Staak O; Zhang HF; Davis T; Keler T; Diehl V; Graziano RF; Engert A
    Blood; 2003 Nov; 102(10):3737-42. PubMed ID: 12881320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
    Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
    Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
    Forero-Torres A; Leonard JP; Younes A; Rosenblatt JD; Brice P; Bartlett NL; Bosly A; Pinter-Brown L; Kennedy D; Sievers EL; Gopal AK
    Br J Haematol; 2009 Jul; 146(2):171-9. PubMed ID: 19466965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab vedotin.
    Deng C; Pan B; O'Connor OA
    Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD30 human IL-2 fusion proteins display strong and specific cytotoxicity in vivo.
    Hirsch B; Brauer J; Fischdick M; Loddenkemper C; Bulfone-Paus S; Stein H; Dürkop H
    Curr Drug Targets; 2009 Feb; 10(2):110-7. PubMed ID: 19199906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.